Quick Takeaways
- Knoll Capital Management, LLC reports institutional holdings through Form 13F filings.
- Latest reported quarter: Q4 2025.
- Latest reported holdings value: $218,013,898.
- Info
- Portfolio
- Significant Ownership
- Insider Ownership
13F Filings History of Knoll Capital Management, LLC
- Latest 13F report
- Q4 2025 - 17 Feb 2026
- Value $
- $218,013,898
- Signature - Title
- Fred Knoll - President
- Location
- Miami, FL
- Summary
- This page shows a list of all the recent 13F filings made by Knoll Capital Management, LLC. Form 13F is required to be filed within 45 days of the end of a calendar quarter. Knoll Capital Management, LLC reported 33 stock holdings with total value $218,013,898 as of Q4 2025. Top holdings included ALDX, BHVN, NUVB, AVDL, and GLD.
Follow Filing Activity
Follow Knoll Capital Management, LLC and return when a new 13F portfolio filing appears.
This tracks SEC filing changes for this page using existing product update flows.
Holdings Value
What Changed
- Most recent filing was accepted on 17 Feb 2026, 16:04.
- Reported value moved from $186,187,654 to $218,013,898.
Why This Matters
- This gives a plain-language read of holdings direction before you open full quarter tables.
- Use the filing links below to verify the exact SEC source document.
Official SEC Source
Backed by Form 13F
Portfolio holdings and changes are grounded in SEC Form 13F filings.
See Original Filing| Quarter | Holdings | Value $ | Bought | Sold | Net | Top Holdings | Form Type | Filing Time |
|---|---|---|---|---|---|---|---|---|
| Q4 2025 | 33 | $218,013,898 | +$36,434,392 | -$12,236,610 | +$24,197,782 | ALDX, BHVN, NUVB, AVDL, GLD | 13F-HR | 17 Feb 2026, 16:04 |
| Q3 2025 | 38 | $186,187,654 | +$6,154,133 | -$10,170,602 | -$4,016,469 | ALDX, BHVN, GLD, ENTX, MGTX | 13F-HR | 14 Nov 2025, 16:21 |
| Q2 2025 | 38 | $138,451,856 | +$1,761,524 | -$4,107,979 | -$2,346,455 | ALDX, Biohaven Pharmactl Hldg Co L, ENTX, GLD, MGTX | 13F-HR | 14 Aug 2025, 16:00 |
| Q1 2025 | 36 | $153,726,702 | +$14,214,323 | -$12,798,297 | +$1,416,026 | ALDX, Biohaven Pharmactl Hldg Co L, ENTX, GLD, MGTX | 13F-HR | 15 May 2025, 16:01 |
| Q4 2024 | 35 | $155,344,595 | +$6,300,100 | -$1,160,528 | +$5,139,572 | BHVN, ALDX, ENTX, VRNA, ALT | 13F-HR | 14 Feb 2025, 20:12 |
| Q3 2024 | 36 | $206,982,383 | +$13,111,062 | -$76,841,183 | -$63,730,121 | APLT, BHVN, ALDX, AVDL, GLD | 13F-HR | 14 Nov 2024, 16:22 |
| Q2 2024 | 35 | $148,407,303 | +$11,524,328 | $0 | +$11,524,328 | APLT, BHVN, ALDX, AVDL, ALT | 13F-HR | 14 Aug 2024, 16:03 |
| Q1 2024 | 34 | $160,736,263 | +$19,176,390 | -$9,570,296 | +$9,606,094 | APLT, BHVN, ALDX, AVDL, GLD | 13F-HR | 15 May 2024, 16:05 |
| Q4 2023 | 32 | $120,759,584 | +$20,940,036 | -$7,513,200 | +$13,426,836 | BHVN, ALDX, APLT, AVDL, SIL | 13F-HR | 14 Feb 2024, 16:07 |
| Q3 2023 | 37 | $95,604,841 | +$24,991,113 | -$1,240,483 | +$23,750,630 | ALDX, APLT, BHVN, AVDL, HOOK | 13F-HR | 14 Nov 2023, 16:17 |
| Q2 2023 | 26 | $80,706,157 | +$20,989,080 | $0 | +$20,989,080 | ALDX, BHVN, AVDL, HOOK, APLT | 13F-HR | 15 Aug 2023, 07:50 |
| Q1 2023 | 24 | $57,025,930 | +$9,265,051 | -$1,914,806 | +$7,350,245 | ALDX, BHVN, VRNA, GDX, ENTX | 13F-HR | 15 May 2023, 16:25 |
| Q4 2022 | 21 | $43,699,802 | +$12,193,384 | -$16,497,027 | -$4,303,643 | ALDX, BHVN, ALT, GDX, SIL | 13F-HR | 14 Feb 2023, 16:06 |
| Q3 2022 | 33 | $169,877,000 | +$2,630,670 | -$11,573,020 | -$8,942,350 | BHVN, ALDX, ENTX, ALT, Anavex Life Sciences Corp | 13F-HR | 14 Nov 2022, 16:03 |
| Q2 2022 | 41 | $171,172,000 | +$6,037,834 | -$3,029,000 | +$3,008,834 | BHVN, ALDX, EIGR, ENTX, ORGS | 13F-HR | 15 Aug 2022, 17:22 |
| Q1 2022 | 41 | $158,723,000 | +$5,244,562 | -$5,683,266 | -$438,704 | BHVN, ENTX, EIGR, ORGS, ALDX | 13F-HR | 16 May 2022, 16:13 |
| Q4 2021 | 38 | $180,648,000 | +$9,017,992 | -$2,854,930 | +$6,163,062 | BHVN, APLT, ENTX, ORGS, Anavex Life Sciemves Corp | 13F-HR | 14 Feb 2022, 16:04 |
| Q3 2021 | 40 | $200,171,000 | +$912,000 | -$7,939,100 | -$7,027,100 | BHVN, APLT, ENTX, ORGS, CRBP | 13F-HR | 15 Nov 2021, 16:05 |
| Q2 2021 | 42 | $189,909,000 | +$9,468,891 | -$971,333 | +$8,497,558 | BHVN, APLT, ENTX, CRBP, ORGS | 13F-HR | 16 Aug 2021, 16:05 |
| Q1 2021 | 39 | $153,044,000 | +$16,214,290 | -$4,736,427 | +$11,477,863 | BHVN, APLT, CRBP, ORGS, ENTX | 13F-HR | 14 Jun 2021, 13:34 |
| Q4 2020 | 31 | $146,130,000 | +$4,617,473 | $0 | +$4,617,473 | BHVN, APLT, EIGR, CRBP, ORGS | 13F-HR | 16 Feb 2021, 16:08 |
| Q3 2020 | 30 | $121,534,000 | +$6,999,995 | -$1,567,611 | +$5,432,384 | BHVN, APLT, CRBP, ORGS, EIGR | 13F-HR | 16 Nov 2020, 16:08 |
| Q2 2020 | 19 | $173,219,000 | +$8,773,752 | -$2,246,000 | +$6,527,752 | BHVN, CRBP, APLT, ABEO, ORGS | 13F-HR | 14 Aug 2020, 16:11 |
| Q1 2020 | 18 | $106,461,000 | +$7,017,768 | -$6,464,975 | +$552,793 | BHVN, CRBP, APLT, ABEO, BX | 13F-HR | 15 May 2020, 16:01 |
| Q4 2019 | 18 | $135,430,000 | +$8,456,864 | -$10,165,000 | -$1,708,136 | BHVN, CRBP, APLT, ABEO, BX | 13F-HR | 14 Feb 2020, 17:08 |
| Q3 2019 | 23 | $109,262,000 | +$7,697,645 | -$1,656,484 | +$6,041,161 | BHVN, CRBP, BX, ABEO, APLT | 13F-HR | 14 Nov 2019, 16:11 |
| Q2 2019 | 22 | $122,151,000 | +$11,963,110 | -$7,330,688 | +$4,632,422 | CRBP, BHVN, ABEO, BX, KRYS | 13F-HR | 14 Aug 2019, 16:04 |
| Q1 2019 | 17 | $131,596,000 | +$24,793,437 | -$3,829,532 | +$20,963,905 | BHVN, CRBP, ABEO, KRYS, BX | 13F-HR | 15 May 2019, 16:06 |
| Q4 2018 | 15 | $87,900,000 | +$460,000 | -$2,516,739 | -$2,056,739 | BHVN, CRBP, ABEO, KRYS, ALDX | 13F-HR | 14 Feb 2019, 16:59 |
| Q3 2018 | 17 | $118,296,000 | +$5,814,543 | -$5,815,854 | -$1,311 | CRBP, ABEO, BHVN, ALDX, ECOR | 13F-HR | 14 Nov 2018, 16:04 |
| Q2 2018 | 19 | $117,674,000 | +$12,637,289 | $0 | +$12,637,289 | ABEO, BHVN, CRBP, ECOR, AMPE | 13F-HR | 14 Aug 2018, 16:03 |
| Q1 2018 | 13 | $97,391,000 | +$741,000 | -$1,541,793 | -$800,793 | ABEO, CRBP, BHVN, AMPE, KRYS | 13F-HR | 15 May 2018, 16:04 |
| Q4 2017 | 12 | $113,433,000 | +$3,043,105 | -$4,228,550 | -$1,185,445 | ABEO, CRBP, BHVN, AMPE, VBLT | 13F-HR | 14 Feb 2018, 16:26 |
| Q3 2017 | 16 | $116,948,000 | +$3,158,111 | -$508,321 | +$2,649,790 | ABEO, BHVN, CRBP, VBLT, AVXL | 13F-HR | 14 Nov 2017, 16:16 |
| Q2 2017 | 15 | $75,436,000 | +$20,282,000 | -$4,691,295 | +$15,590,705 | CRBP, BHVN, ABEO, AVXL, VBLT | 13F-HR | 14 Aug 2017, 16:28 |
| Q1 2017 | 17 | $66,328,000 | +$13,101,299 | -$3,955,389 | +$9,145,910 | CRBP, ABEO, VBLT, AVXL, NLNK | 13F-HR | 15 May 2017, 16:17 |
| Q4 2016 | 17 | $56,996,000 | +$9,217,619 | -$6,562,289 | +$2,655,330 | CRBP, ABEO, VBLT, AVXL, RTTR | 13F-HR | 14 Feb 2017, 17:07 |
| Q3 2016 | 18 | $57,031,000 | +$869,000 | -$268,603,302 | -$267,734,302 | CRBP, ABEO, SYN, VBLT, CEMP | 13F-HR | 14 Nov 2016, 18:23 |
| Q2 2016 | 22 | $308,530,000 | +$3,967,000 | -$1,430,911 | +$2,536,089 | MDVN, CRBP, SYN, ADHD, AMPE | 13F-HR | 15 Aug 2016, 16:06 |
| Q1 2016 | 22 | $246,277,000 | +$1,638,000 | -$217,008 | +$1,420,992 | MDVN, SYN, AMPE, CRBP, ADHD | 13F-HR | 16 May 2016, 16:09 |
| Q4 2015 | 21 | $269,729,000 | +$7,778,000 | -$1,345,551 | +$6,432,449 | MDVN, AMPE, SYN, ADHD, CEMP | 13F-HR | 17 Feb 2016, 14:29 |
| Q3 2015 | 19 | $235,563,000 | +$95,783,436 | -$40,047 | +$95,743,389 | MDVN, AMPE, SYN, ADHD, ABEO | 13F-HR | 16 Nov 2015, 16:14 |
| Q2 2015 | 19 | $310,193,000 | +$14,149,521 | -$695,581 | +$13,453,940 | MDVN, SYN, AMPE, ADHD, ABEO | 13F-HR | 14 Aug 2015, 16:23 |
| Q1 2015 | 17 | $343,460,000 | +$7,970,120 | -$7,890,582 | +$79,538 | MDVN, AMPE, SYN, ADHD, NLNK | 13F-HR | 15 May 2015, 16:10 |
| Q4 2014 | 14 | $254,119,000 | +$4,754,694 | -$1,180,023 | +$3,574,671 | MDVN, AMPE, SYN, ADHD, NLNK | 13F-HR | 17 Feb 2015, 16:05 |
| Q3 2014 | 1 | $2,458,000 | $0 | $0 | $0 | ORPN | New Holdings | 09 Dec 2014, 10:35 |
| Q3 2014 | 15 | $257,075,000 | +$3,937,836 | -$4,270,409 | -$332,573 | MDVN, AMPE, ADHD, KERX, ORPN | 13F-HR | 14 Nov 2014, 16:11 |
| Q2 2014 | 15 | $224,399,000 | +$1,281,000 | -$2,461,857 | -$1,180,857 | MDVN, AMPE, ADHD, KERX, SYN | 13F-HR | 14 Aug 2014, 16:16 |
| Q1 2014 | 16 | $193,229,000 | +$9,142,689 | -$16,009,482 | -$6,866,793 | MDVN, AMPE, ADHD, SYN, KERX | 13F-HR | 15 May 2014, 16:41 |
| Q4 2013 | 13 | $197,526,000 | $0 | $0 | $0 | MDVN, AMPE, ADHD, KERX, SQNM | 13F-HR | 14 Feb 2014, 16:13 |